Natera (NASDAQ:NTRA) CEO Sells $819,415.64 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,076 shares of Natera stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $266.39, for a total transaction of $819,415.64. Following the transaction, the chief executive officer owned 99,897 shares in the company, valued at $26,611,561.83. This represents a 2.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, July 28th, Steven Leonard Chapman sold 3,580 shares of Natera stock. The stock was sold at an average price of $254.07, for a total value of $909,570.60.
• On Monday, July 27th, Steven Leonard Chapman sold 2,190 shares of Natera stock. The stock was sold at an average price of $260.49, for a total transaction of $570,473.10.
• On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72.

Natera Stock Up 21.4%

Shares of Natera stock opened at $322.10 on Friday. Natera, Inc. has a 52 week low of $149.38 and a 52 week high of $323.01. The stock’s 50-day simple moving average is $254.03 and its 200-day simple moving average is $223.79. The company has a market capitalization of $46.13 billion, a price-to-earnings ratio of -236.84 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 11.82% and a negative net margin of 7.11%.The firm’s revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.74) EPS. On average, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Investors Weigh In On Natera

A number of institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Natera in the 2nd quarter valued at about $2,962,770,000. Coatue Management LLC lifted its position in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after buying an additional 2,463,008 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Natera by 94.7% during the fourth quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after purchasing an additional 2,420,263 shares in the last quarter. Norges Bank purchased a new position in Natera in the 4th quarter valued at about $372,398,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Canaccord Genuity Group set a $375.00 target price on shares of Natera in a research report on Friday. Sanford C. Bernstein started coverage on shares of Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 target price for the company. JPMorgan Chase & Co. increased their price objective on Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a research note on Friday. Guggenheim raised their target price on shares of Natera from $270.00 to $290.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, The Goldman Sachs Group began coverage on Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price target for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $299.65.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.